

TOP MARK CAPITAL MANAGEMENT LLC

Report For the Quarter Ended

March 31, 2024

416 13th Street

2nd Floor

San Diego, CA 92101


E: contact@topmarkcapital.com

T: +1 (646) 470-3016

INDEX

ASSETS UNDER MANAGEMENT.....	3
MANAGEMENT’S LETTER TO PARTNERS.....	4
TOP MARK CAPITAL PARTNERS LP.....	7
PARTNERSHIP LETTER & PERFORMANCE UPDATE.....	8
PORTFOLIO UPDATE & COMMENTARY.....	13
TOP MARK HEALTH PARTNERS LP.....	19
PARTNERSHIP LETTER & PERFORMANCE UPDATE.....	20
PORTFOLIO UPDATE & COMMENTARY.....	22
IMPORTANT DISCLAIMER.....	28
REFERENCES.....	29

ASSETS UNDER MANAGEMENT



Dear Partners and Prospective Partners,

We are pleased to report a strong start to the year for both of our investment partnerships. As always, we encourage you to focus on the cumulative results over the long-term and avoid getting overly excited (or disappointed) by the quarterly gyrations. For the first quarter of 2024 Top Mark Capital Partners (TMCP) delivered a net return of 17.9% and a gross return of 18.1%. Top Mark Health Partners (TMHP) posted a net return of 5.2% and a gross return of 5.8%, concluding its first twelve months with an 11% net gain¹²³. The ensuing pages delve deeper into the performance of our Partnerships.

As long time admirers of Charlie Munger's quick wit and wisdom, we were delighted to attend the Berkshire Hathaway annual shareholders meeting⁴ and the preceding VALUExBRK⁵ event. Both events paid considerable tribute to the life of Mr. Munger, who passed away last year. They are available to stream, for those who missed out.

The Berkshire Hathaway annual meeting, often dubbed 'Woodstock for Capitalists,' is a unique experience. Attendees from around the globe gather to celebrate Buffett, Munger, and the diverse businesses under Berkshire's umbrella.

Buffett emphasized the virtues of buying and holding—a principle we encourage our Partners to also embrace. An extreme representation of this level of patience is Ruth

¹ Net Performance figures are presented at the fund level, after management fees and performance fees

² Gross Performance figures are presented at the fund level, before management fees and performance fees

³ Please review the Important Disclaimers on Page 28

⁴ *Warren Buffett Presides over the 2024 Berkshire Hathaway Annual Shareholders Meeting — 5/4/24.*

⁵ *VALUExBRK 2024.m*

Gottesman, a longtime Berkshire investor, who was honored at the meeting for making a \$1 billion donation to Albert Einstein College of Medicine in the form of Berkshire stock. Similarly, we aspire to compound our Partners capital at a high rate, over the long term, thus enabling you to make decisions for yourselves as to how you will impact the world.

You'll notice a new chart this quarter, the "AUM" chart on page 3. This chart doesn't provide much in the way of meaningful information. That said, it is emblematic of our journey from "side project" to full-time investment operation. We are almost 12 years into our journey and looking forward to the next 12.

For those committed to long-term outperformance, our approach has consistently delivered satisfactory returns. We're always here for a deeper conversation about either partnership and appreciate referrals to individuals who share our philosophy.

As our Partner, expect these quarterly letters, offering insights into our investment strategies and performance. Top Mark's administrator, Formidium Fund Management Services, will continue to provide quarterly account statements and annual audited financials. Please alert us if any communication has not reached you.

Our focus on long-term success suggests that less frequent updates may better serve you by minimizing the distractions of short-term market noise. For those interested in more frequent updates, we share our insights weekly on the Telltales podcast. Subscribe at [telltales.us](https://www.telltales.us) for episode notifications.

Our edge lies in two areas: our capital allocation acumen and your patience as investors. It's this forward-looking perspective that sets us apart from the short-term crowd and defines our Partnership's essence.

When it comes to patience, we are fortunate to be surrounded by like-minded, long-term investors. Only by looking further out than the short-term crowd can we expect to outperform them. We are an investment partnership, not a hedge fund, and the relationship we seek with our Partners is different.

In the event that you share our temperament and perspective, we invite you to consider subscribing to one of our partnerships. The next contribution window for both new and existing Partners is July 1, 2024, so please get in touch and start the process.

As always, we deeply appreciate your confidence and support.

Sincerely,



Michael Nicoletti

A handwritten signature in black ink, appearing to be "Michael Nicoletti", written over a light blue horizontal line.

Jason Wallace

A handwritten signature in black ink, appearing to be "Jason Wallace", written over a light blue horizontal line.

TOP MARK CAPITAL PARTNERS LP


Partnership Letter

For the Quarter ended March 31, 2024



PARTNERSHIP LETTER & PERFORMANCE UPDATE

CUMULATIVE RETURNS ON \$1,000⁶



⁶ TMCP figures are presented at the fund level, net of fees (i.e., management fees, costs, and performance fees). SPXTR: S&P 500 Total Return. BRK: Berkshire Hathaway Stock. QQQ: Nasdaq 100 Index ETF. VC Index: Cambridge Associates US Venture Capital Index. Please review the Important Disclaimers on Page 28.

TMCP CUMULATIVE RETURNS TO DATE⁷

To: 3-31-2024, From:	TMCP % Gross Return	TMCP % Net Return	S&P 500 Total Return	Berkshire Hathaway	VC Index	QQQ
3/31/2023	31%	29%	30%	36%	-3%	39%
3/31/2022	18%	16%	20%	20%	-21%	24%
3/31/2021	39%	31%	39%	64%	0%	42%
3/31/2020	137%	107%	117%	133%	64%	139%
3/31/2019	221%	170%	102%	111%	77%	155%
3/31/2018	223%	171%	121%	112%	114%	189%
3/31/2017	715%	513%	152%	154%	140%	253%
3/31/2016	1736%	1136%	195%	197%	157%	332%
3/31/2015	1665%	1080%	200%	192%	168%	352%
Since Inception	1657%	1056%	354%	390%	354%	659%
<i>Annualized Since Inception</i>	28%	24%	14%	15%	14%	19%

⁷ TMCP % Gross Return is at the fund level before management and performance fees; TMCP % Net Return is at the fund level, net of all fees. SPXTR: S&P 500 Total Return. BRK: Berkshire Hathaway Stock. QQQ: Nasdaq 100 Index ETF. VC Index: Cambridge Associates US Venture Capital Index. Please review the Important Disclaimers on Page 27.

The current quarter's results neither elate nor disappoint us. Short-term fluctuations are less indicative of our strategy's effectiveness than long-term compounded returns. **Over the last five years Top Mark Capital Partners (TMCP) delivered a robust 170% return⁸, outpacing the S&P 500's 102%.** Since our inception in September 2012, our capital has grown at an impressive annualized rate of 24%, significantly surpassing the S&P 500's 14%. To date, TMCP's total return stands at 1056%, dwarfing the S&P 500's 354%. The table above illustrates this point.

We include the S&P 500 Total Return Index, a Nasdaq 100 index fund, Berkshire Hathaway stock, and the Cambridge Associates US Venture Capital index as gauges against other potential investments. These are not explicit benchmarks but provide a cumulative perspective. We believe our disciplined process will yield superior long-term returns compared to broad market indices like the S&P 500.

We understand the myriad of investment choices available to you and take seriously the responsibility of managing your capital. Our commitment is evident as the majority of our liquid net worth is invested alongside yours.

For those interested in annual or quarterly returns data, please refer to the tables on the following pages. However, focusing solely on short-term periods can lead to misconceptions about the success of any investment strategy.

⁸ Performance is at the fund level, net of all fees (i.e., management fees, costs, and performance fees) and rounded to the nearest whole percentage. Please review the Important Disclaimers on Page 27

TMCP ANNUAL RETURNS DATA⁹

Period	TMCP % Gross Return	TMCP % Net Return	S&P 500 Total Return	Berkshire Hathaway	VC Index	QQQ
2024Q1	18%	18%	11%	17%		9%
2023	24%	23%	26%	16%	-4%	55%
2022	-30%	-31%	-18%	4%	-21%	-33%
2021	41%	35%	29%	30%	53%	27%
2020	64%	54%	18%	2%	36%	48%
2019	79%	65%	31%	11%	19%	39%
2018	15%	14%	-4%	3%	18%	0%
2017	58%	48%	22%	22%	11%	33%
2016	133%	109%	12%	23%	0%	7%
2015	-5%	-6%	1%	-12%	13%	10%
2014	9%	9%	14%	27%	22%	19%
2013	-6%	-7%	32%	33%	29%	37%
2012Q4	0%	0%	0%	4%	7%	0%

⁹ TMCP % Gross Return is at the fund level before management and performance fees; TMCP % Net Return is at the fund level, net of all fees. SPXTR: S&P 500 Total Return. BRK: Berkshire Hathaway Stock. QQQ: Nasdaq 100 Index ETF. VC Index: Cambridge Associates US Venture Capital Index. Please review the Important Disclaimers on Page 28.

TMCP QUARTERLY RETURNS DATA¹⁰

Quarter Ended	TMCP % Gross Return	TMCP % Net Return	S&P 500 Total Return	Berkshire Hathaway	VC Index	QQQ
March 31, 2024	18%	18%	11%	17%		9%
December 31, 2023	-1%	-2%	12%	2%	0%	14%
September 30, 2023	0%	0%	-3%	3%	-3%	-3%
June 30, 2023	12%	12%	9%	11%	0%	15%
March 31, 2023	12%	12%	7%	-1%	-1%	21%
December 31, 2022	3%	3%	8%	15%	-7%	0%
September 30, 2022	-4%	-4%	-5%	-1%	-2%	-4%
June 30, 2022	-19%	-19%	-16%	-23%	-9%	-23%
March 31, 2022	-13%	-13%	-5%	17%	-4%	-9%
December 31, 2021	13%	11%	11%	10%	7%	11%
September 30, 2021	3%	3%	1%	-2%	10%	1%
June 30, 2021	16%	14%	9%	9%	12%	11%
March 31, 2021	5%	4%	6%	11%	17%	2%
December 31, 2020	5%	4%	12%	9%	14%	13%
September 30, 2020	15%	13%	9%	20%	12%	12%
June 30, 2020	35%	30%	21%	-2%	9%	30%
March 31, 2020	0%	0%	-20%	-20%	-3%	-10%
December 31, 2019	24%	21%	9%	9%	6%	13%
September 30, 2019	7%	6%	2%	-2%	-1%	1%
June 30, 2019	2%	2%	4%	6%	7%	4%
March 31, 2019	33%	27%	14%	-2%	6%	17%
December 31, 2018	-53%	-49%	-14%	-4%	2%	-17%
September 30, 2018	29%	27%	8%	13%	5%	8%
June 30, 2018	24%	22%	3%	-6%	6%	7%
March 31, 2018	52%	44%	-1%	1%	4%	3%
December 31, 2017	14%	12%	7%	8%	3%	7%
September 30, 2017	13%	11%	4%	8%	3%	6%
June 30, 2017	29%	-26%	3%	2%	1%	4%
March 31, 2017	-5%	-5%	6%	2%	3%	12%
December 31, 2016	121%	101%	4%	13%	0%	0%
September 30, 2016	6%	5%	4%	0%	3%	11%
June 30, 2016	1%	1%	2%	2%	1%	-1%
March 31, 2016	-2%	-2%	1%	8%	-3%	-2%
December 31, 2015	-1%	-1%	7%	1%	2%	10%
September 30, 2015	-2%	-2%	-6%	-5%	0%	-5%
June 30, 2015	0%	0%	0%	-6%	7%	2%
March 31, 2015	-3%	-3%	1%	-4%	4%	3%
December 31, 2014	1%	1%	5%	9%	10%	5%
September 30, 2014	-1%	-1%	1%	9%	3%	5%
June 30, 2014	3%	3%	5%	1%	3%	7%
March 31, 2014	5%	5%	2%	5%	5%	0%
December 31, 2013	1%	1%	11%	4%	13%	12%
September 30, 2013	0%	0%	5%	1%	7%	11%
June 30, 2013	-1%	-2%	3%	8%	4%	4%
March 31, 2013	-6%	-6%	11%	17%	3%	6%
December 31, 2012	0%	0%	0%	4%	1%	0%

¹⁰ TMCP % Gross Return is at the fund level before management and performance fees; TMCP % Net Return is at the fund level, net of all fees. SPXTR: S&P 500 Total Return. BRK: Berkshire Hathaway Stock. QQQ: Nasdaq 100 Index ETF. VC Index: Cambridge Associates US Venture Capital Index. Please review the Important Disclaimers on Page 28.

PORTFOLIO UPDATE & COMMENTARY

<u>Theme</u>	<u>% of Portfolio</u>			<u>Dividend /</u>
	<u>12/31/2023</u>	<u>3/31/2024</u>	<u>Change</u>	<u>YTM</u>
Software is Eating the World	31%	35%	3.8%	0.2%
Health	28%	27%	-0.8%	0.0%
TIIA	14%	12%	-2.0%	12.0%
Open RAN, 5G, & the Future of Wireless Networks	5%	5%	-0.4%	16.9%
Semiconductors are the Teeth	8%	2%	-5.9%	1.0%
Metals Powered Economy	2%	2%	-0.4%	0.0%
Yield Curve Inversion	<u>-3%</u>	<u>0%</u>	3.0%	
Stocks, Convertible Bonds, & Private Credit	85%	82%	-2.7%	2.3%
<u>Cash</u>	<u>15%</u>	<u>18%</u>	2.7%	
Total Partnership	100%	100%		

The table above outlines our Partnership's thematic allocations as of March 31, 2024. Partners will find the following pages detail our allocations and activity for each theme.


Prospective partners are encouraged to review our 2022 Annual letter which details our investment philosophy¹¹. In the event that our approach resonates with you, we'd be happy to discuss it in greater detail.

¹¹ If you are unfamiliar with our process and philosophy, please review our [2022 Annual letter](#), or reach out to us directly to request a copy

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Health

<i>Health</i>	<i>% of Portfolio</i>		<i>Change</i>	<i>Dividend / YTM</i>
	<i>12/31/2023</i>	<i>3/31/2024</i>		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]



[REDACTED]
[REDACTED]
[REDACTED]

Semiconductors are the Teeth

<i>Semiconductors are the Teeth</i>	<i>% of Portfolio</i>		<i>Change</i>	<i>Dividend / YTM</i>
	<i>12/31/2023</i>	<i>3/31/2024</i>		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]

Metals Powered Economy

<i>Metals Powered Economy</i>	<i>% of Portfolio</i>		<i>Change</i>	<i>Dividend / YTM</i>
	<i>12/31/2023</i>	<i>3/31/2024</i>		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Open RAN, 5G, & the Future of Wireless Networks

<i>Open RAN, 5G, & the Future of Wireless Networks</i>	<i>% of Portfolio</i>		<i>Change</i>	<i>Dividend / YTM</i>
	<i>12/31/2023</i>	<i>3/31/2024</i>		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

Yield Curve Inversion

<i>Yield Curve Inversion</i>	<i>% of Portfolio</i>		<i>Change</i>	<i>Dividend / YTM</i>
	<i>12/31/2023</i>	<i>3/31/2024</i>		
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]

¹³ The 2023 Q1 Letter is available [here](#), or reach out directly to request a copy

¹⁴ The 2023 Q4 Letter is available [here](#), or reach out directly to request a copy

TOP MARK HEALTH PARTNERS LP

Partnership Letter

For the Quarter ended March 31, 2024



PARTNERSHIP LETTER &
PERFORMANCE UPDATE¹⁵

Quarter Ended	TMHP % Gross Return	TMHP % Net Return	S&P 500 Healthcare
3/31/2024	6%	5%	8%
12/31/2023	2%	2%	6%
9/30/2023	0%	-1%	-3%
6/30/2023	5%	4%	3%

Partnership interests in Top Mark Health Partners (TMHP) increased in price by 5.8% gross and 5.2% net in Q1. Over the last 12 months TMHP returned 13% gross and 11% net, compared to the 14% gain of the S&P 500 Healthcare Sector index¹⁶¹⁷. During this first year of the Partnership's existence, your managers were looking for the best companies to own while constructing a portfolio of holdings that we are satisfied with. Therefore, a substantial portion of the portfolio was held in Treasuries over the last twelve months.

We added two new holdings in Q1. Both companies have FDA-approved products in the early stages of commercialization that we feel are best-in-class for their respective indications. Both operate in growing markets.

¹⁵Please review the Important Disclaimers on Page 28

¹⁶ TMHP % Gross Return is at the fund level before management and performance fees; TMHP % Net Return is at the fund level, net of all fees.

¹⁷ The S&P 500 Healthcare Sector Total Return index is included, not as an explicit benchmark, but as the simple gauge against another investment you could have made.

One of these companies in particular exhibits a capital allocation strategy that we are especially drawn to. It addresses our most pressing concerns regarding capital allocation in this industry. In many cases biotech companies are established based on a specific competency. But, due to the risks of clinical failures and the fact that an approved therapy only has a finite time under patent protection, there is a strong temptation to venture away from core competencies in pursuit of the next new thing. Typically, that next new thing is funded out of an R&D budget. Preclinical assets, especially outside of the core competency, carry a high level of risk and require a long-term commitment that may not be appropriate to fund out of cash flow.

The optimal capital allocation strategy (in our opinion) therefore should be to spin promising new research into a subsidiary company. This allows venture and other early stage investors to evaluate the merits of the research, determine a valuation, and bear the risk of financing those early stage programs. By following this strategy, the parent company retains upside in the form of equity and royalties, while preserving flexibility in their capital allocation strategy.

We opened one new research position during the quarter. This oncology focused biotech exhibits some of the key characteristics we look for in a company. Chiefly, they have a second generation tyrosine kinase inhibitor (TKI) on the market generating the cash flow necessary to fund development of their next generation TKI. We intend to hold this research position until we have more clarity on the level of differentiation this new drug exhibits, and the company gains resolution in an ongoing patent dispute.

PORTFOLIO UPDATE & COMMENTARY

Below you will find commentary on each of the Health Partnership's holdings. Some sections provide an update on long held positions, others introduce new holdings. Additional context can be found in previous partnership letters.

<i>Positions</i>	<i>% of Portfolio</i>		<i>Change</i>
	<i>12/31/2023</i>	<i>3/31/2024</i>	
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]


[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]



IMPORTANT DISCLAIMER

Past performance is no guarantee of future results. Investing in equities and fixed income involves risk, including the possible loss of principal. The investment performance presentation contains historical data and information relating to the performance of certain investments. These figures should not be considered as a guarantee or a reliable indicator of future performance. Investment returns and the value of an investment can go up or down, and there is no assurance that any investment strategy will achieve its objectives, generate profits, or avoid losses. Investing in financial markets inherently involves a certain degree of risk and speculation. The value of investments, and the income generated from them, can fluctuate due to various factors, including but not limited to market conditions, economic changes, interest rates, and political events. As such, there is always the potential for loss, and you should only invest funds that you can afford to lose. The S&P 500 Index is included to allow you to compare your returns against an unmanaged capitalization-weighted index of 500 stocks designed to measure performance of the broad domestic economy through changes in the aggregate market value of the 500 stocks representing all major industries. The NASDAQ 100 Index measures the performance of the largest 100 stocks on the NASDAQ.

IMPORTANT DISCLOSURES. The information herein is provided by Top Mark Capital Management LLC ("Top Mark Capital") and: (a) is for general, informational purposes only; (b) is not tailored to the specific investment needs of any specific person or entity; and (c) should not be construed as investment advice. Top Mark Capital makes no representation with respect to the accuracy, completeness or timeliness of the information herein. Top Mark Capital assumes no obligation to update or revise such information. In addition, certain information herein has been provided by and/or is based on third party sources, and, although Top Mark Capital believes this information to be reliable, Top Mark Capital has not independently verified such information and is not responsible for third-party errors. You should not assume that any investment discussed herein will be profitable or that any investment decisions in the future will be profitable. Investing in securities involves risk, including the possible loss of principal.

REFERENCES

VALUExBRK 2024: Life Lessons from Charlie Munger, Mohnish Pabrai, William Green and Others. Accessed June 4, 2024. <https://www.youtube.com/watch?v=PhuQc6OFGaA>.

Warren Buffett Presides over the 2024 Berkshire Hathaway Annual Shareholders Meeting — 5/4/24, 2024. <https://www.youtube.com/watch?v=X3wLdzddRtI>.

